1. Home
  2. SPHL vs DRMA Comparison

SPHL vs DRMA Comparison

Compare SPHL & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Springview Holdings Ltd Class A Ordinary Shares

SPHL

Springview Holdings Ltd Class A Ordinary Shares

HOLD

Current Price

$2.42

Market Cap

5.5M

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.22

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPHL
DRMA
Founded
2002
2014
Country
Singapore
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5M
5.6M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
SPHL
DRMA
Price
$2.42
$1.22
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
15.1K
469.8K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$650.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$0.95
52 Week High
$25.11
$6.22

Technical Indicators

Market Signals
Indicator
SPHL
DRMA
Relative Strength Index (RSI) 39.47 43.99
Support Level $2.19 $1.14
Resistance Level $3.04 $1.41
Average True Range (ATR) 0.10 0.14
MACD -0.01 -0.03
Stochastic Oscillator 25.29 0.00

Price Performance

Historical Comparison
SPHL
DRMA

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd conducts its operations through its indirect wholly-owned subsidiary, which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of work, including new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment in the development of construction projects. It derives maximum revenue from its Residential Customers.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: